Drug intelligence / Profile preview

encorafenib

Development stage: Approved
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Encorafenib is a small molecule kinase inhibitor used as an antineoplastic agent. It selectively inhibits the BRAF serine/threonine kinase, particularly in tumors with activating BRAF V600E or V600K mutations. By blocking mutant BRAF, encorafenib disrupts the MAPK/ERK signaling pathway, leading to decreased cell proliferation and tumor growth. It is primarily indicated for use in combination with other agents (binimetinib or cetuximab) for unresectable or metastatic melanoma, metastatic colorectal cancer (CRC), and non-small cell lung cancer (NSCLC) harboring specific BRAF mutations. Encorafenib was developed by Array BioPharma and Novartis[3][5].

Brand names: Braftovi
Other names: encorafenibum

Targets

RAF1 (c-Raf-1 (Y340D/Y341D))BRAF (B-Raf proto-oncogene, serine/threonine kinase)

Beyond the preview

Go deeper on encorafenib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on encorafenib.

Explore the full profile